Below are some of the best trades in the Biopharma Stock Sector since January 2013. I have gathered my research from a pretty good stock investment forum, 4-Trader.
It's all free. I would never ask you to pay for anything on my site. No catches, no gimmicks.
If you want to search for other Sectors or other Countries, you can check them out here:
These are highly potential breakout stocks that I have researched and just posting their results and how to learn more about these Top Stocks in the Healthcare Sector. More Specifically Biotech and Pharmaceutical Stocks that I predict will be doing very well in the next year with the stock market doing well and the Obamacare being implemented in 2014. There were a lot to choose from so I pick the best ones that I thought had potential for further gains.
Make Money Off Obamacare
As bad as Obamacare is for business, I think it will improve the Healthcare Sector in the upcoming year and these are all good stocks that I would recommend. But you can perform your own due diligence yourself, this are the ones that stuck out to me.
Top 4 Biopharma Trades
These are the all the best trades since January, most are above 50% in stock share growth. Most have higher potentials for further earnings. These are my own personal 4 picks that I thought were the best of the bunch.
Surperformance© rating of Santarus, Inc.
Trading Rating : Investor Rating :
Duration : Auto. 2 month 3 month 6 month 9 month 1 year 2 years 5 years 10 years Max. Period : Day Week
Sales 2013 346 M EBIT 2013 72,4 M Net income 2013 69,1 M Debt 2013 - Yield 2013 -
Sales 2014 442 M EBIT 2014 143 M Net income 2014 109 M Debt 2014 - Yield 2014 -
PER 2013 27,09 PER 2014 17,87 Capi. / Sales 2013 4,52x Capi. / Sales 2014 3,53x Capitalization 1 563 M
Latest news on SANTARUS, INC.
3d ago SANTARUS, INC. : Santarus to Hold Second Quarter 2013 Financial Results Conferen..07/18 SANTARUS, INC. : Santarus Completes Patient Enrollment in CONTRIBUTE Study with ..07/02 SANTARUS, INC. : Santarus to Present at JMP Securities Healthcare Conference06/25 SANTARUS, INC. : Santarus and Pharming Announce Poster Presentation of Pivotal C..06/24 SANTARUS, INC. : Data Presentations, Orphan Drug Designations, FDA Applications ..06/21 SANTARUS, INC. : Santarus and VeroScience Announce CYCLOSET (bromocriptine mesyl..06/18 SANTARUS, INC. : Santarus and Pharming Announce FDA Acceptance for Review of RUC..06/17 SANTARUS, INC. : Santarus President & CEO Gerald Proehl Honored as San Diego Ern..05/17 SANTARUS, INC. : Santarus Announces UCERIS (budesonide) Poster Presentations at ..05/15 SANTARUS, INC. : Santarus Announces Exercise in Full of Option to Purchase Addit..05/10 SANTARUS, INC. : Santarus Announces Pricing of Secondary Common Stock Offering b..05/09 SANTARUS, INC. : Santarus Announces Launch of a Proposed Secondary Common Stock ..
4-Traders Strategies on SANTARUS, INC.
Surperformance© rating of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Auto. 2 month 3 month 6 month 9 month 1 year 2 years 5 years 10 years Max. Period : Day Week
Sales 2013 92,3 M EBIT 2013 4,38 M Net income 2013 3,87 M Debt 2013 4,80 M Yield 2013 -
Sales 2014 123 M EBIT 2014 26,7 M Net income 2014 19,5 M Debt 2014 27,3 M Yield 2014 -
PER 2013 179,05 PER 2014 15,61 EV / Sales 2013 3,12x EV / Sales 2014 2,52x Capitalization 283 M
Latest news on SUCAMPO PHARMACEUTICALS, I
1d ago SUCAMPO PHARMACEUTICALS, INC. : Sucampo Pharmaceuticals Announces Second Quarter..06/26 SUCAMPO PHARMACEUTICALS, INC. : Sucampo Receives $10 Million Milestone Payment f..05/30 SUCAMPO PHARMACEUTICALS, INC. : Sucampo Pharmaceuticals Announces Webcast of Its..05/29 SUCAMPO PHARMACEUTICALS, INC. : Sucampo Appoints Kei Tolliver to Board of Direct..05/29 SUCAMPO PHARMACEUTICALS, INC. : Sucampo Pharmaceuticals Achieves Orphan Designat..05/15 SUCAMPO PHARMACEUTICALS, INC. : Sucampo to be Added to the NASDAQ Biotechnology ..05/13 SUCAMPO PHARMACEUTICALS, INC. : Sucampo Pharmaceuticals to Host Update on AMITIZ..05/07 SUCAMPO PHARMACEUTICALS, INC. : Reports First Quarter 2013 Financial and Operati..04/30 SUCAMPO PHARMACEUTICALS, INC. : Sucampo Pharmaceuticals Announces First Quarter ..04/24 SUCAMPO PHARMACEUTICALS, INC. : And Revolution Lighting Technologies News (NASDA..04/23 SUCAMPO PHARMACEUTICALS, INC. : FDA Approves Supplemental New Drug Application f..03/29 SUCAMPO PHARMACEUTICALS, INC. : Sucampo Pharmaceuticals to Present at 20th Annua..
Surperformance© rating of Chelsea Therapeutics Inter
Trading Rating : Investor Rating : -
Chart CHELSEA THERAPEUTICS INTER
Duration : Auto. 2 month 3 month 6 month 9 month 1 year 2 years 5 years 10 years Max. Period : Day Week
Sales 2013 - EBIT 2013 -22,0 M Net income 2013 -21,8 M Finance 2013 0,12 M Yield 2013 -
Sales 2014 22,7 M EBIT 2014 -42,8 M Net income 2014 -42,6 M Debt 2014 - Yield 2014 -
PER 2013 - PER 2014 Capi. / Sales 2013 0 Capi. / Sales 2014 9,12x Capitalization 207 M
Latest news on CHELSEA THERAPEUTICS INTER
Surperformance© rating of Lannett Company, Inc.
Trading Rating : Investor Rating :
Chart LANNETT COMPANY, INC.
Duration : Auto. 2 month 3 month 6 month 9 month 1 year 2 years 5 years 10 years Max. Period : Day Week
Sales 2013 149 M EBIT 2013 16,6 M Net income 2013 11,8 M Debt 2013 - Yield 2013 -
Sales 2014 167 M EBIT 2014 19,1 M Net income 2014 11,8 M Debt 2014 - Yield 2014 -
PER 2013 33,06 PER 2014 33,58 Capi. / Sales 2013 2,60x Capi. / Sales 2014 2,32x Capitalization 387 M
Latest news on LANNETT COMPANY, INC.
06/03 LANNETT COMPANY, INC. : 06/03/2013 - Lannett Names James Maher To Board Of Direc..06/03 LANNETT COMPANY, INC. : Lannett Names James Maher to Board of Directors05/08 LANNETT COMPANY, INC. : 05/08/2013 - Lannett Reports Record Fiscal 2013 Third Qu..05/08 LANNETT COMPANY, INC. : Lannett Reports Record Fiscal 2013 Third Quarter Financi..04/30 LANNETT COMPANY, INC. : Lannett Announces Preliminary Fiscal 2013 Third Quarter ..04/23 LANNETT COMPANY, INC. : Lannett to Present at Needham's 12th Annual Healthcare C..03/12 LANNETT COMPANY, INC. : 03/12/2013 - Lannett To Present At 25th Annual Roth Conf..03/12 LANNETT COMPANY, INC. : Lannett to Present at 25th Annual Roth Conference March ..02/07 LANNETT COMPANY, INC. : Lannett Reports Strong Financial Results for Fiscal 2013..02/02 LANNETT COMPANY, INC. : 01/31/2013 - Lannett Announces Preliminary Financial Res..01/31 LANNETT COMPANY, INC. : Lannett Announces Preliminary Financial Results for Fisc..2012 LANNETT COMPANY, INC. : 12/10/2012 - Lannett Universal Shelf Registration Statem..
